Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Histol Histopathol. 2012 Mar;27(3):257-61. doi: 10.14670/HH-27.257.
Bcl-2-associated athanogene (BAG) family proteins share the BAG domain, which is characterized by their interaction with a variety of partners (heat shock proteins, steroid hormone receptors, Raf-1 and others) and is involved in regulating a number of cellular processes. BAG3, also known as CAIR-1 or Bis, mediates protein delivery to proteasome and modulates apoptosis by interfering with cytochrome c release, apoptosome assembly and other events in the cellular death program. Moreover, it takes part in the processes of cell adhesion and migration. It has been shown that, in human cancer cells, including lymphocytic and myeloblastic leukemic cells, BAG3 sustains cell survival and underlies resistance to chemotherapy, through down-modulation of apoptosis. BAG3 knocking down could enhance the effectiveness of chemotherapy. This review summarizes the physiological and pathological roles of BAG3 in cancer cells and its potential as a therapeutic target of human malignancies.
Bcl-2 相关抗凋亡基因（BAG）家族蛋白共享 BAG 结构域，其特征在于与多种伴侣（热休克蛋白、甾体激素受体、Raf-1 等）相互作用，并参与调节许多细胞过程。BAG3 又称 CAIR-1 或 Bis，通过干扰细胞色素 c 释放、凋亡体组装和细胞死亡程序中的其他事件，介导蛋白质向蛋白酶体的输送，并调节细胞凋亡。此外，它还参与细胞黏附和迁移过程。已经表明，在人类癌细胞中，包括淋巴细胞性和髓样白血病细胞，BAG3 通过下调细胞凋亡来维持细胞存活并导致对化疗的耐药性。敲低 BAG3 可以增强化疗的效果。本综述总结了 BAG3 在癌细胞中的生理和病理作用及其作为人类恶性肿瘤治疗靶点的潜力。
